In the AFFIRM-AHF trial of 1,108 patients stabilised after acute heart failure with iron deficiency, intravenous ferric carboxymaltose lowered total heart failure hospitalisations against placebo (rate ratio 0.74) without changing cardiovascular death.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
In the AFFIRM-AHF trial of 1,108 patients stabilised after acute heart failure with iron deficiency, intravenous ferric carboxymaltose lowered total heart failure hospitalisations against placebo (rate ratio 0.74) without changing cardiovascular death. · pmid:33197395
In two randomized trials in iron-deficiency anemia, hypophosphatemia followed ferric carboxymaltose in about 74-75% of patients against about 8% after iron isomaltoside (ferric derisomaltose). · pmid:32016310
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Established100%
Proportion of the 2 claims about Ferric carboxymaltose standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Ferric carboxymaltose yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. · pmid 32016310 · 2020
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. · pmid 33197395 · 2020
Observational evidence· resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.